LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 7 of total 7

Search options

  1. Article ; Online: The Impact of Different Implantation Sites and Sex on the Differentiation of Human Pancreatic Endoderm Cells Into Insulin-Secreting Cells In Vivo.

    Saber, Nelly / Ellis, Cara E / Iworima, Diepiriye G / Baker, Robert K / Rezania, Alireza / Kieffer, Timothy J

    Diabetes

    2023  Volume 72, Issue 5, Page(s) 590–598

    Abstract: Few studies have examined the differentiation of human embryonic stem cell (hESC)-derived pancreatic endoderm cells (PECs) in different implantation sites. Here, we investigate the influence of implantation site and recipient sex on the differentiation ... ...

    Abstract Few studies have examined the differentiation of human embryonic stem cell (hESC)-derived pancreatic endoderm cells (PECs) in different implantation sites. Here, we investigate the influence of implantation site and recipient sex on the differentiation of hESC-derived PECs in vivo. Male and female mice were implanted with 5 × 106 hESC-derived PECs under the kidney capsule, in the gonadal fat pad, or subcutaneously within macroencapsulation (TheraCyte) devices. PECs implanted within TheraCyte devices developed glucose-stimulated human C-peptide secretion faster than cells implanted under the kidney capsule or in the gonadal fat pad. Interestingly, hESC-derived PECs implanted under the kidney capsule in females developed glucose-stimulated human C-peptide faster than in males and secreted higher levels of arginine-stimulated glucagon and glucagon-like peptide 1 than other implantation sites. Furthermore, hESC-derived grafts collected from the kidney capsule and gonadal fat pad sites displayed a mix of endocrine and ductal cells as well as contained cysts, whereas TheraCyte device grafts displayed mostly endocrine cells and cysts were not observed. Here we demonstrate that the macroencapsulated subcutaneous site and the female recipient can promote faster differentiation of hESC-derived PECs to endocrine cells in mice.
    Article highlights: Few studies have directly compared the differentiation of human embryonic stem cell-derived progenitors in different implantation sites in male and female recipients. We investigated whether the site of implantation and/or the sex of the recipient influenced the differentiation of pancreatic progenitors in vivo in mice. Mice implanted with cells in macroencapsulation devices contained fewer off-target structures and developed stimulated insulin release faster than other implant sites, while females implanted with cells under the kidney capsule developed stimulated insulin release before males. Macroencapsulation devices reduced the formation of off-target cells from human embryonic stem cell-derived progenitors, a useful characteristic for clinical applications.
    MeSH term(s) Humans ; Male ; Female ; Mice ; Animals ; Insulin-Secreting Cells ; C-Peptide ; Endoderm/transplantation ; Cell Differentiation ; Glucose
    Chemical Substances C-Peptide ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2023-03-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 80085-5
    ISSN 1939-327X ; 0012-1797
    ISSN (online) 1939-327X
    ISSN 0012-1797
    DOI 10.2337/db22-0692
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Thyroid Hormone Levels Correlate With the Maturation of Implanted Pancreatic Endoderm Cells in Patients With Type 1 Diabetes.

    Ramzy, Adam / Saber, Nelly / Bruin, Jennifer E / Thompson, David M / Kim, Peter T W / Warnock, Garth L / Kieffer, Timothy J

    The Journal of clinical endocrinology and metabolism

    2023  Volume 109, Issue 2, Page(s) 413–423

    Abstract: Background: Macroencapsulated pancreatic endoderm cells (PECs) can reverse diabetes in rodents and preclinical studies revealed that thyroid hormones in vitro and in vivo bias PECs to differentiate into insulin-producing cells. In an ongoing clinical ... ...

    Abstract Background: Macroencapsulated pancreatic endoderm cells (PECs) can reverse diabetes in rodents and preclinical studies revealed that thyroid hormones in vitro and in vivo bias PECs to differentiate into insulin-producing cells. In an ongoing clinical trial, PECs implanted in macroencapsulation devices into patients with type 1 diabetes were safe but yielded heterogeneous outcomes. Though most patients developed meal responsive C-peptide, levels were heterogeneous and explanted grafts had variable numbers of surviving cells with variable distribution of endocrine cells.
    Methods: We measured circulating triiodothyronine and thyroxine levels in all patients treated at 1 of the 7 sites of the ongoing clinical trial and determined if thyroid hormone levels were associated with the C-peptide or glucagon levels and cell fate of implanted PECs.
    Results: Both triiodothyronine and thyroxine levels were significantly associated with the proportion of cells that adopted an insulin-producing fate with a mature phenotype. Thyroid hormone levels were inversely correlated to circulating glucagon levels after implantation, suggesting that thyroid hormones lead PECs to favor an insulin-producing fate over a glucagon-producing fate. In mice, hyperthyroidism led to more rapid maturation of PECs into insulin-producing cells similar in phenotype to PECs in euthyroid mice.
    Conclusion: These data highlight the relevance of thyroid hormones in the context of PEC therapy in patients with type 1 diabetes and suggest that a thyroid hormone adjuvant therapy may optimize cell outcomes in some PEC recipients.
    MeSH term(s) Humans ; Mice ; Animals ; Diabetes Mellitus, Type 1/metabolism ; C-Peptide/metabolism ; Thyroxine/metabolism ; Triiodothyronine/metabolism ; Endoderm/metabolism ; Endoderm/transplantation ; Glucagon/metabolism
    Chemical Substances C-Peptide ; Thyroxine (Q51BO43MG4) ; Triiodothyronine (06LU7C9H1V) ; Glucagon (9007-92-5)
    Language English
    Publishing date 2023-09-04
    Publishing country United States
    Document type Journal Article
    ZDB-ID 3029-6
    ISSN 1945-7197 ; 0021-972X
    ISSN (online) 1945-7197
    ISSN 0021-972X
    DOI 10.1210/clinem/dgad499
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article: Human A2-CAR T cells reject HLA-A2+ human islets transplanted into mice without inducing graft versus host disease.

    Ellis, Cara E / Mojibian, Majid / Ida, Shogo / Fung, Vivian C W / Skovsø, Søs / McIver, Emma / O'Dwyer, Shannon / Webber, Travis D / Braam, Mitchell J S / Saber, Nelly / Kieffer, Timothy J / Levings, Megan K

    bioRxiv : the preprint server for biology

    2023  

    Abstract: Background: Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell mediated destruction of pancreatic beta-cells. Islet transplantation is an effective therapy, but its success is limited by islet quality and availability along with the ... ...

    Abstract Background: Type 1 diabetes (T1D) is an autoimmune disease characterised by T cell mediated destruction of pancreatic beta-cells. Islet transplantation is an effective therapy, but its success is limited by islet quality and availability along with the need for immunosuppression. New approaches include use of stem cell-derived insulin-producing cells and immunomodulatory therapies, but a limitation is the paucity of reproducible animal models in which interactions between human immune cells and insulin-producing cells can be studied without the complication of xenogeneic graft-
    Methods: We expressed an HLA-A2-specific chimeric antigen receptor (A2-CAR) in human CD4+ and CD8+ T cells and tested their ability to reject HLA-A2+ islets transplanted under the kidney capsule or anterior chamber of the eye of immunodeficient mice. T cell engraftment, islet function and xGVHD were assessed longitudinally.
    Results: The speed and consistency of A2-CAR T cells-mediated islet rejection varied depending on the number of A2-CAR T cells and the absence/presence of co-injected peripheral blood mononuclear cells (PBMCs). When <3 million A2-CAR T cells were injected, co-injection of PBMCs accelerated islet rejection but also induced xGVHD. In the absence of PBMCs, injection of 3 million A2-CAR T cells caused synchronous rejection of A2+ human islets within 1 week and without xGVHD for 12 weeks.
    Conclusions: Injection of A2-CAR T cells can be used to study rejection of human insulin-producing cells without the complication of xGVHD. The rapidity and synchrony of rejection will facilitate in vivo screening of new therapies designed to improve the success of isletreplacement therapies.
    Language English
    Publishing date 2023-02-23
    Publishing country United States
    Document type Preprint
    DOI 10.1101/2023.02.23.529741
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Human A2-CAR T Cells Reject HLA-A2 + Human Islets Transplanted Into Mice Without Inducing Graft-versus-host Disease.

    Ellis, Cara E / Mojibian, Majid / Ida, Shogo / Fung, Vivian C W / Skovsø, Søs / McIver, Emma / O'Dwyer, Shannon / Webber, Travis D / Braam, Mitchell J S / Saber, Nelly / Sasaki, Shugo / Lynn, Francis C / Kieffer, Timothy J / Levings, Megan K

    Transplantation

    2023  Volume 107, Issue 9, Page(s) e222–e233

    Abstract: Background: Type 1 diabetes is an autoimmune disease characterized by T-cell-mediated destruction of pancreatic beta-cells. Islet transplantation is an effective therapy, but its success is limited by islet quality and availability along with the need ... ...

    Abstract Background: Type 1 diabetes is an autoimmune disease characterized by T-cell-mediated destruction of pancreatic beta-cells. Islet transplantation is an effective therapy, but its success is limited by islet quality and availability along with the need for immunosuppression. New approaches include the use of stem cell-derived insulin-producing cells and immunomodulatory therapies, but a limitation is the paucity of reproducible animal models in which interactions between human immune cells and insulin-producing cells can be studied without the complication of xenogeneic graft-versus-host disease (xGVHD).
    Methods: We expressed an HLA-A2-specific chimeric antigen receptor (A2-CAR) in human CD4 + and CD8 + T cells and tested their ability to reject HLA-A2 + islets transplanted under the kidney capsule or anterior chamber of the eye of immunodeficient mice. T-cell engraftment, islet function, and xGVHD were assessed longitudinally.
    Results: The speed and consistency of A2-CAR T-cell-mediated islet rejection varied depending on the number of A2-CAR T cells and the absence/presence of coinjected peripheral blood mononuclear cells (PBMCs). When <3 million A2-CAR T cells were injected, coinjection of PBMCs accelerated islet rejection but also induced xGVHD. In the absence of PBMCs, injection of 3 million A2-CAR T cells caused synchronous rejection of A2 + human islets within 1 wk and without xGVHD for 12 wk.
    Conclusions: Injection of A2-CAR T cells can be used to study rejection of human insulin-producing cells without the complication of xGVHD. The rapidity and synchrony of rejection will facilitate in vivo screening of new therapies designed to improve the success of islet-replacement therapies.
    MeSH term(s) Humans ; Mice ; Animals ; HLA-A2 Antigen ; Receptors, Chimeric Antigen ; Leukocytes, Mononuclear ; Graft vs Host Disease ; Islets of Langerhans Transplantation ; Insulins ; Graft Rejection/prevention & control
    Chemical Substances HLA-A2 Antigen ; Receptors, Chimeric Antigen ; Insulins
    Language English
    Publishing date 2023-08-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 208424-7
    ISSN 1534-6080 ; 0041-1337
    ISSN (online) 1534-6080
    ISSN 0041-1337
    DOI 10.1097/TP.0000000000004709
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Sex Differences in Maturation of Human Embryonic Stem Cell-Derived β Cells in Mice.

    Saber, Nelly / Bruin, Jennifer E / O'Dwyer, Shannon / Schuster, Hellen / Rezania, Alireza / Kieffer, Timothy J

    Endocrinology

    2018  Volume 159, Issue 4, Page(s) 1827–1841

    Abstract: Pancreatic progenitors derived from human embryonic stem cells (hESCs) are now in clinical trials for insulin replacement in patients with type 1 diabetes. Animal studies indicate that pancreatic progenitor cells can mature into a mixed population of ... ...

    Abstract Pancreatic progenitors derived from human embryonic stem cells (hESCs) are now in clinical trials for insulin replacement in patients with type 1 diabetes. Animal studies indicate that pancreatic progenitor cells can mature into a mixed population of endocrine cells, including glucose-responsive β cells several months after implantion. However, it remains unclear how conditions in the recipient may influence the maturation and ultimately the function of these hESC-derived cells. Here, we investigated the effects of (1) pregnancy on the maturation of human stage 4 (S4) pancreatic progenitor cells and (2) the impact of host sex on both S4 cells and more mature stage 7 (S7) pancreatic endocrine cells implanted under the kidney capsule of immunodeficient SCID-beige mice. Pregnancy led to increased proliferation of endogenous pancreatic β cells, but did not appear to affect proliferation or maturation of S4 cells at midgestation. Interestingly, S4 and S7 cells both acquired glucose-stimulated C-peptide secretion in females before males. Moreover, S4 cells lowered fasting blood glucose levels in females sooner than in males, whereas the responses with S7 cells were similar. These data indicate that the host sex may impact the maturation of hESC-derived cells in vivo and that this effect can be minimized by more advanced differentiation of the cells before implantation.
    MeSH term(s) Animals ; C-Peptide/metabolism ; Cell Differentiation/drug effects ; Cell Differentiation/physiology ; Cell Proliferation/drug effects ; Cell Proliferation/physiology ; Female ; Glucose/pharmacology ; Human Embryonic Stem Cells/cytology ; Human Embryonic Stem Cells/drug effects ; Human Embryonic Stem Cells/metabolism ; Humans ; Insulin-Secreting Cells/cytology ; Insulin-Secreting Cells/drug effects ; Insulin-Secreting Cells/metabolism ; Male ; Mice ; Sex Characteristics
    Chemical Substances C-Peptide ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2018-02-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 427856-2
    ISSN 1945-7170 ; 0013-7227
    ISSN (online) 1945-7170
    ISSN 0013-7227
    DOI 10.1210/en.2018-00048
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Hypothyroidism Impairs Human Stem Cell-Derived Pancreatic Progenitor Cell Maturation in Mice.

    Bruin, Jennifer E / Saber, Nelly / O'Dwyer, Shannon / Fox, Jessica K / Mojibian, Majid / Arora, Payal / Rezania, Alireza / Kieffer, Timothy J

    Diabetes

    2016  Volume 65, Issue 5, Page(s) 1297–1309

    Abstract: Pancreatic progenitors derived from human embryonic stem cells (hESCs) are a potential source of transplantable cells for treating diabetes and are currently being tested in clinical trials. Yet, how the milieu of pancreatic progenitor cells, including ... ...

    Abstract Pancreatic progenitors derived from human embryonic stem cells (hESCs) are a potential source of transplantable cells for treating diabetes and are currently being tested in clinical trials. Yet, how the milieu of pancreatic progenitor cells, including exposure to different factors after transplant, may influence their maturation remains unclear. Here, we examined the effect of thyroid dysregulation on the development of hESC-derived progenitor cells in vivo. Hypothyroidism was generated in SCID-beige mice using an iodine-deficient diet containing 0.15% propyl-2-thiouracil, and hyperthyroidism was generated by addition of L-thyroxine (T4) to drinking water. All mice received macroencapsulated hESC-derived progenitor cells, and thyroid dysfunction was maintained for the duration of the study ("chronic") or for 4 weeks posttransplant ("acute"). Acute hyperthyroidism did not affect graft function, but acute hypothyroidism transiently impaired human C-peptide secretion at 16 weeks posttransplant. Chronic hypothyroidism resulted in severely blunted basal human C-peptide secretion, impaired glucose-stimulated insulin secretion, and elevated plasma glucagon levels. Grafts from chronic hypothyroid mice contained fewer β-cells, heterogenous MAFA expression, and increased glucagon(+) and ghrelin(+) cells compared to grafts from euthyroid mice. Taken together, these data suggest that long-term thyroid hormone deficiency may drive the differentiation of human pancreatic progenitor cells toward α- and ε-cell lineages at the expense of β-cell formation.
    MeSH term(s) Animals ; Antithyroid Agents/poisoning ; Biomarkers/blood ; Biomarkers/metabolism ; Cell Differentiation ; Cell Line ; Cells, Immobilized/cytology ; Cells, Immobilized/pathology ; Cells, Immobilized/transplantation ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/metabolism ; Diabetes Mellitus, Type 1/pathology ; Diabetes Mellitus, Type 1/surgery ; Disease Models, Animal ; Heterografts/cytology ; Heterografts/metabolism ; Heterografts/pathology ; Human Embryonic Stem Cells/cytology ; Human Embryonic Stem Cells/metabolism ; Human Embryonic Stem Cells/pathology ; Human Embryonic Stem Cells/transplantation ; Humans ; Hyperthyroidism/chemically induced ; Hyperthyroidism/complications ; Hypothyroidism/complications ; Hypothyroidism/etiology ; Insulin-Secreting Cells/cytology ; Insulin-Secreting Cells/metabolism ; Insulin-Secreting Cells/pathology ; Insulin-Secreting Cells/transplantation ; Iodine/deficiency ; Male ; Mice, SCID ; Propylthiouracil/poisoning ; Random Allocation ; Thyroxine/poisoning ; Transplantation, Heterologous ; Transplantation, Heterotopic
    Chemical Substances Antithyroid Agents ; Biomarkers ; Propylthiouracil (721M9407IY) ; Iodine (9679TC07X4) ; Thyroxine (Q51BO43MG4)
    Language English
    Publishing date 2016-05
    Publishing country United States
    Document type Comparative Study ; Journal Article
    ZDB-ID 80085-5
    ISSN 1939-327X ; 0012-1797
    ISSN (online) 1939-327X
    ISSN 0012-1797
    DOI 10.2337/db15-1439
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Treating diet-induced diabetes and obesity with human embryonic stem cell-derived pancreatic progenitor cells and antidiabetic drugs.

    Bruin, Jennifer E / Saber, Nelly / Braun, Natalie / Fox, Jessica K / Mojibian, Majid / Asadi, Ali / Drohan, Campbell / O'Dwyer, Shannon / Rosman-Balzer, Diana S / Swiss, Victoria A / Rezania, Alireza / Kieffer, Timothy J

    Stem cell reports

    2015  Volume 4, Issue 4, Page(s) 605–620

    Abstract: Human embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes has not been reported. An immunodeficient model of type 2 diabetes was ...

    Abstract Human embryonic stem cell (hESC)-derived pancreatic progenitor cells effectively reverse hyperglycemia in rodent models of type 1 diabetes, but their capacity to treat type 2 diabetes has not been reported. An immunodeficient model of type 2 diabetes was generated by high-fat diet (HFD) feeding in SCID-beige mice. Exposure to HFDs did not impact the maturation of macroencapsulated pancreatic progenitor cells into glucose-responsive insulin-secreting cells following transplantation, and the cell therapy improved glucose tolerance in HFD-fed transplant recipients after 24 weeks. However, since diet-induced hyperglycemia and obesity were not fully ameliorated by transplantation alone, a second cohort of HFD-fed mice was treated with pancreatic progenitor cells combined with one of three antidiabetic drugs. All combination therapies rapidly improved body weight and co-treatment with either sitagliptin or metformin improved hyperglycemia after only 12 weeks. Therefore, a stem cell-based therapy may be effective for treating type 2 diabetes, particularly in combination with antidiabetic drugs.
    MeSH term(s) Animals ; Cell Differentiation ; Cell- and Tissue-Based Therapy ; Diabetes Mellitus, Type 2/etiology ; Diabetes Mellitus, Type 2/metabolism ; Diabetes Mellitus, Type 2/therapy ; Diet/adverse effects ; Diet, High-Fat/adverse effects ; Disease Models, Animal ; Gene Expression Profiling ; Glucose/metabolism ; Human Embryonic Stem Cells/cytology ; Humans ; Hyperglycemia ; Hypoglycemic Agents/pharmacology ; Insulin Resistance ; Insulin-Secreting Cells/cytology ; Insulin-Secreting Cells/metabolism ; Islets of Langerhans/cytology ; Liver/anatomy & histology ; Liver/metabolism ; Mice ; Mice, SCID ; Obesity/etiology ; Obesity/metabolism ; Obesity/therapy ; Organ Size ; Pancreas/cytology ; Phenotype ; Stem Cell Transplantation ; Stem Cells/cytology
    Chemical Substances Hypoglycemic Agents ; Glucose (IY9XDZ35W2)
    Language English
    Publishing date 2015-04-14
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2720528-9
    ISSN 2213-6711 ; 2213-6711
    ISSN (online) 2213-6711
    ISSN 2213-6711
    DOI 10.1016/j.stemcr.2015.02.011
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top